title: Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
abstract: BACKGROUND
  The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear.
  
  
  METHODS
  Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery.
  
  
  RESULTS
  After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15% on multivariable analysis (hazard ratio 1.15 95% confidence interval 1.04.-1.28, p=0.006).
  
  
  CONCLUSIONS
  The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.
authors.affiliation: Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Rocca
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Cancello
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Bagnardi
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Sandri
authors.forename: Rosalba
authors.initials: R
authors.lastname: Torrisi
authors.forename: Laura
authors.initials: L
authors.lastname: Zorzino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Viale
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Pietri
authors.forename: Paolo
authors.initials: P
authors.lastname: Veronesi
authors.forename: Silvia
authors.initials: S
authors.lastname: Dellapasqua
authors.forename: Francesco
authors.initials: F
authors.lastname: Ferrucci
authors.forename: Alberto
authors.initials: A
authors.lastname: Luini
authors.forename: Harriet
authors.initials: H
authors.lastname: Johansson
authors.forename: Raffaella
authors.initials: R
authors.lastname: Ghisini
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery*; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D066246:ErbB Receptors / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D019990:Perioperative Care; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human